By Sneha S K May 31 (Reuters) - Johnson & Johnson's prostate cancer drug Erleada used with hormone-blocking therapy six ...

By doing hormone therapy up front in prostate cancer cases, the hope was to shrink the relapse rate after surgery. Results ...

CHICAGO -- A paradigm-changing clinical trial in prostate cancer showed that perioperative apalutamide (Erleada) and androgen ...

Prostatectomy and radiation therapy show no survival difference for low-risk prostate cancer, but higher-risk cases require careful treatment consideration. The ProtecT trial supports active ...

Johnson & Johnson's prostate cancer drug Erleada, reportedly used alongside standard home-blocking therapy before and after ...

For men who undergo a radical prostatectomy for the treatment of prostate cancer, post-surgery radiation therapy can play a vital role in reducing the risk of recurrence. Despite its benefits, many ...

In patients undergoing RP with adjuvant radiation, PLND showed no survival benefit, regardless of prostate cancer risk group or number of lymph nodes removed. Pelvic lymph node dissection (PLND) ...

Researchers have found long-term evidence that actively monitoring localized prostate cancer is a safe alternative to ...

Most patients with prostate cancer undergoing treatment experience complications associated with worse quality of life or new health risks. Prostate cancer surgery and radiation therapy are associated ...

For men who undergo a radical prostatectomy for the treatment of prostate cancer, post-surgery radiation therapy can play a vital role in reducing the risk of recurrence. Despite its benefits, many ...

Johnson & Johnson's Erleada drug, combined with hormone therapy, significantly reduces the risk of prostate cancer spread and ...